Keying Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keying Xu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Annette Hasenburg
Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße, 1, 55131 Mainz, Germany
11 shared publications - Catherine A. Schnabel
BioTheranostics, Inc., San Diego, CA
11 shared publications - Christos Markopoulos
Medical School, National and Kapodistrian University of Athens, Athens, Greece
11 shared publications - Cornelis J. H. van de Velde
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
11 shared publications - Daniel Rea
Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
11 shared publications - Elizabeth Mallon
Department of Pathology, NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom
11 shared publications
Latest Publications
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a function of continuous BCIN+ for N1 patients (N=1625); C: risk of 10-year late DR as a function of continuous BCI for N0 HER2- patients (N=1063); D: risk of 10-year late DR as a function of continuous BCIN+ for N1 HER2- patients (N=1394).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a function of continuous BCIN+ for N1 patients (N=1625); C: risk of 10-year late DR as a function of continuous BCI for N0 HER2- patients (N=1063); D: risk of 10-year late DR as a function of continuous BCIN+ for N1 HER2- patients (N=1394).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a function of continuous BCIN+ for N1 patients (N=1625); C: risk of 10-year late DR as a function of continuous BCI for N0 HER2- patients (N=1063); D: risk of 10-year late DR as a function of continuous BCIN+ for N1 HER2- patients (N=1394).
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a function of continuous BCIN+ for N1 patients (N=1625); C: risk of 10-year late DR as a function of continuous BCI for N0 HER2- patients (N=1063); D: risk of 10-year late DR as a function of continuous BCIN+ for N1 HER2- patients (N=1394).
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.